March 19, 2021 11:14 AM EDT
News Briefing

FDA ac­cepts Bris­tol My­er­s' pitch for for­mer MyoKar­dia drug; Clo­vis' Rubra­ca aces ad­vanced ovar­i­an can­cer study

Max Gelman

Senior Editor

Kyle Blankenship

Nicole DeFeudis

Editor

The pro­gram at the cen­ter­piece of Bris­tol My­ers Squibb’s buy­out of MyoKar­dia just got one step clos­er to gain­ing po­ten­tial FDA ap­proval.

BMS …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Bio­haven's myo­statin in­hibitor miss­es pri­ma­ry end­point in spinal mus­cu­lar at­ro­phy tri­al

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

A service from the Financial Times